Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

IIR 18-037 – HSR Study

 
IIR 18-037
Therapeutic Interventions to Access Outcomes and Disparities in Chronic Kidney Disease Among Veterans
Csaba P Kovesdy, MD
Memphis VA Medical Center, Memphis, TN

Funding Period: January 2020 - December 2025
Portfolio Assignment: Healthcare Informatics

Abstract

Chronic kidney disease (CKD) affects approximately 10% of the general population and is especially common among US veterans, affecting up to 36% of all VA users during FY2006-2014. All-cause and cardiovascular (CV) morbidity and mortality are extremely high in veterans with CKD and ESRD, and African American veterans have substantially higher rates of CKD and CV disease than whites. Traditional risk factors of cardiovascular disease such as hypercholesterolemia, hypertension and obesity often show seemingly anomalous, inverse associations with adverse outcomes among individuals with CKD and ESRD. To date there are few therapeutic interventions proven to prevent the development of CKD, delay its progression, or decrease morbidity/mortality in patients with CKD. There is also a lack of race-specific application of clinical interventions, in spite of evidence suggesting that African-Americans may respond differently to various therapies. The lack of clinical end point driven randomized controlled trials in this population necessitates robust epidemiologic studies to provide preliminary results in support of future clinical trials, and to offer large- scale, widely applicable evidence to inform clinical practice in cases when clinical trials are not feasible. Our proposal will expand on our previous work using data obtained from the national VA research database, which offers uniquely detailed sociodemographic and clinical information on millions of individuals across all parts of the US. The Specific Aims of our proposal are: Aim 1: Examine the effect of interventions on clinical outcomes in veterans with non-dialysis dependent CKD (NDD-CKD) overall and by race-ethnicity. Aim 2: Examine the effect of interventions on incident CKD and on all-cause and cause-specific mortality, CHD, incident stroke and incident CHF in veterans with normal baseline estimated GFR, overall and by race- ethnicity. Aim 3: Employ powerful graph theoretical algorithms and scalable supercomputer implementations to test and extend the validity of the findings from Aims 1 and 2, and to help elucidate hidden factors and highlight previously unknown relationships between condition, risk, treatment and outcome. Next steps: This four-year project will generate a wealth of information to examine the above outcomes of patients with all levels of kidney function, and could have significant implications for the care of US veterans and also for patients with kidney diseases in general. Clinicians and guideline committees could use information generated from our research to determine the most likely benefits for interventions without clinical trial evidence, and this could help prioritization of healthcare expenditures and drug formularies. Clinical trialists could also use information generated from our research to determine likely effect sizes for various interventions and various subgroups that may be most prone to benefit from interventions. Furthermore,

External Links for this Project

NIH Reporter

Grant Number: I01HX002680-01A1
Link: https://reporter.nih.gov/project-details/9833889


Dimensions for VA

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

Learn more about Dimensions for VA.

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.     Search Dimensions for this project

PUBLICATIONS:


Journal Articles

  1. Sumida K, Shrestha P, Mallisetty Y, Thomas F, Gyamlani G, Streja E, Kalantar-Zadeh K, Kovesdy CP. Anti-Tumor Necrosis Factor Therapy and Risk of Kidney Function Decline and Mortality in Inflammatory Bowel Disease. JAMA Network Open. 2024 Apr 1; 7(4):e246822, DOI: 10.1001/jamanetworkopen.2024.6822. [view]
  2. Shrestha P, Paul S, Sumida K, Thomas F, Surbhi S, Naser AM, Streja E, Rhee CM, Kalantar-Zadeh K, Kovesdy CP. Association of iron therapy with incidence of chronic kidney disease. European journal of haematology. 2023 Dec 1; 111(6):872-880. [view]
  3. Lu JL, Shrestha P, Streja E, Kalantar-Zadeh K, Kovesdy CP. Association of long-term aspirin use with kidney disease progression. Frontiers in medicine. 2023 Dec 4; 10:1283385. [view]
  4. Paul S, Shrestha P, Sumida K, Thomas F, Surbhi S, Naser AM, Streja E, Rhee CM, Kalantar-Zadeh K, Kovesdy CP. Association of oral iron replacement therapy with kidney failure and mortality in CKD patients. Clinical kidney journal. 2023 Nov 1; 16(11):2082-2090. [view]
  5. Hassan W, Shrestha P, Sumida K, Thomas F, Sweeney PL, Potukuchi PK, Rhee CM, Streja E, Kalantar-Zadeh K, Kovesdy CP. Association of Uric Acid-Lowering Therapy With Incident Chronic Kidney Disease. JAMA Network Open. 2022 Jun 1; 5(6):e2215878. [view]
  6. Sumida K, Mallisetty Y, Shrestha P, Vo A, Khan RN, Thomas F, Kalantar-Zadeh K, Kovesdy CP. Comparative Effectiveness of Lubiprostone and Stool Softeners on Risk of Kidney Outcomes in Patients with CKD. Clinical journal of the American Society of Nephrology : CJASN. 2025 Jul 1 DOI: 10.2215/CJN.0000000779. [view]
  7. Jain N, Johnson LR, Jadvani D, Shrestha P, Kovesdy CP. Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD. Kidney360. 2025 Jul 21 DOI: 10.34067/KID.0000000918. [view]
  8. Narasaki Y, Kovesdy CP, You AS, Sumida K, Mallisetty Y, Surbhi S, Thomas F, Amin AN, Streja E, Kalantar-Zadeh K, Rhee CM. Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study. Lancet Regional Health. Americas. 2024 Aug 1; 36:100814, DOI: 10.1016/j.lana.2024.100814. [view]
  9. Kalantar DS, Takahashi R, Shen JI, Tran D, Ismail A, Pena EL, Abichequer-Beer M, Thomas F, Lu JL, Sumida K, Kalantar-Zadeh K, Kovesdy CP, Rhee CM. The Association of Antiemetics Use with Incident Chronic Kidney Disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2025 Jun 28 DOI: 10.1053/j.jrn.2025.06.004. [view]
  10. Takahashi R, Shen J, Tran D, Elali I, Dai T, Shah A, Dukkipati R, Ismail A, Sumida K, Thomas F, Rhee CM, Kovesdy CP, Kalantar-Zadeh K. The Association of Fibrate Use with Kidney Outcomes and Mortality. Clinical journal of the American Society of Nephrology : CJASN. 2025 Apr 7; 20(6):779-787, DOI: 10.2215/CJN.0000000683. [view]
  11. Takahashi R, Bui TA, Elali I, Tran D, Sumida K, Thomas F, Dukkipati R, Shah A, Rhee CM, Kovesdy CP, Kalantar-Zadeh K. The Association of Niacin Use with Kidney Outcomes and Mortality. American Journal of Nephrology. 2025 Jan 27; 1-11, DOI: 10.1159/000543098. [view]
  12. Surbhi S, Mallisetty Y, Shrestha P, Sumida K, Thomas F, Kalantar-Zadeh K, Kovesdy CP. Trends in Opioid Prescriptions and Short-term Mortality Outcomes for Patients With Chronic Kidney Disease and Chronic Pain. Mayo Clinic proceedings. 2025 Jul 1; 100(7):1248-1251, DOI: 10.1016/j.mayocp.2025.03.028. [view]


DRA: Kidney Disorders
DRE: Epidemiology, Treatment - Observational, TRL - Applied/Translational
Keywords: None at this time.
MeSH Terms: None at this time.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.
<--- --->